s-1033 and Neurodegenerative-Diseases

A recent review of kinase inhibitors in clinical trials for brain cancer noted differences in the properties of these compounds relative to the mean property parameters associated with drugs marketed for CNS-associated conditions. However, many of these kinase drugs arose from opportunistic observations of brain activity, rather than design or flow schemes focused on optimizing CNS penetration. Thus, this digest examines kinase inhibitors that have been developed specifically for neurodegenerative indications such as Alzheimer's or Parkinson's disease, and considers design, flow scheme, and the physicochemical properties associated with compounds that have demonstrated brain penetrance.

Topics: Animals; Drug Discovery; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Neurosciences; Protein Kinase Inhibitors; Protein Kinases